(Public, NASDAQ:CRME)   Watch this stock  
Find more results for CRME
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 5.84 - 11.31
Open     -
Vol / Avg. 0.00/77,881.00
Mkt cap 158.15M
P/E     -
Div/yield     -
EPS -1.12
Shares 16.77M
Beta 1.51
Inst. own 279%
Aug 10, 2015
Q2 2015 Cardiome Pharma Corp Earnings Release (Estimated) Add to calendar
Jun 16, 2015
Cardiome Pharma Corp Annual Shareholders Meeting (Estimated) - 11:30AM EDT - Add to calendar
May 13, 2015
Q1 2015 Cardiome Pharma Corp Earnings Call
May 13, 2015
Q1 2015 Cardiome Pharma Corp Earnings Release
Mar 12, 2015
Q4 2014 Cardiome Pharma Corp Earnings Call
Mar 12, 2015
Q4 2014 Cardiome Pharma Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -92.98% -60.67%
Operating margin -92.09% -55.21%
EBITD margin - -48.05%
Return on average assets -50.32% -37.41%
Return on average equity -128.20% -91.63%
Employees 85 -
CDP Score - -


1441 Creekside Dr 6th Floor
+1-604-6776905 (Phone)
+1-604-6776915 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cardiome Pharma Corp. (Cardiome) is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular therapies which improves the health of patients suffering from heart disease. Cardiome has two products that are marketed as in-hospital cardiology products, BRINAVESS and AGGRASTAT which are available in markets across the United States. BRINAVESS (vernakalant (IV)), is approved in the European Union and in approximately 50 countries for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults and for use in post-cardiac surgery patients with atrial fibrillation of three days or less. AGGRASTAT (tirofiban HCL) is a reversible GP IIb/IIIa inhibitor (an intravenous anti-platelet drug) for use in Acute Coronary Syndrome patients. Cardiome also has several pre-clinical projects directed at various therapeutic indications.

Officers and directors

Robert W. Rieder Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
William L. Hunter M.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Jennifer Archibald Chief Financial Officer
Bio & Compensation  - Reuters
Sheila M. Grant Chief Operating Officer
Bio & Compensation  - Reuters
David D. McMasters J.D. General Counsel
Bio & Compensation  - Reuters
Richard M. Glickman Lead Independent Director
Age: 56
Bio & Compensation  - Reuters
W. James O'Shea Director
Bio & Compensation  - Reuters
Peter W. Roberts CPA Independent Director
Bio & Compensation  - Reuters
Harold H. Shlevin Independent Director
Age: 65
Bio & Compensation  - Reuters